Clinical Trials | January 06, 2026
BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Subscribe To Our Newsletter & Stay Updated
